Naproxen sodium (NapS) or naproxen (Nap) v placebo for acute postoperative pain in adults*
| Outcome at 4–6 hours | Number of trials (n) | Drug and dosage | Weighted event rates (NapS/Nap v placebo) | RBI (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *NS = not significant; other abbreviations defined in glossary. Weighted event rates, RBI, RRR, RRI, and CI calculated from data in article (based on a fixed effects model). | |||||
| ⩾50% pain relief | 6 (n = 500) | NapS, 550 mg | 50% v 12% | 318% (193 to 497) | 3 (3 to 4) |
| 3 (n = 334) | NapS/Nap, 440/400 mg | 50% v 11% | 380% (175 to 738) | 3 (3 to 4) | |
| 2 (n = 202) | NapS/Nap, 220/200 mg | 44% v 16% | 187% (60 to 415) | 4 (3 to 6) | |
| RRR (CI) | |||||
| ⩾1 adverse event | 5 (n = 392) | NapS, 550 mg | 24% v 27% | 11% (−25 to 37) | NS |
| RRI (CI) | NNH (CI) | ||||
| 2 (n = 257) | NapS/Nap, 440/400 mg | 22% v 17% | 32% (−22 to 124) | NS | |
| 1 (n = 122) | NapS/Nap, 220/200 mg | 26% v 12% | 121% (−10 to 443) | NS | |
